Positive News SentimentPositive NewsNASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $8.63 -0.44 (-4.85%) Closing price 04:00 PM EasternExtended Trading$8.82 +0.18 (+2.14%) As of 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AUPH alerts:Sign Up Key Stats Today's Range$8.61▼$9.1350-Day Range$7.47▼$9.0752-Week Range$5.20▼$10.67Volume2.01 million shsAverage Volume1.41 million shsMarket Capitalization$1.17 billionP/E Ratio30.82Dividend YieldN/APrice Target$11.50Consensus RatingBuy Company Overview Aurinia Pharmaceuticals Inc. is a clinical‐stage biopharmaceutical company dedicated to developing and commercializing novel therapies for autoimmune and inflammatory diseases. Its flagship product, Lupkynis (voclosporin), is approved for the treatment of lupus nephritis, a severe kidney inflammation that arises from systemic lupus erythematosus. Aurinia’s research pipeline also encompasses investigational candidates targeting other immune‐mediated conditions, leveraging proprietary small‐molecule platform technologies to modulate key pathways involved in disease progression. Since its founding in 1993 and its relocation of global headquarters to Victoria, British Columbia, Aurinia has expanded its operational footprint with a strategic presence in the United States and Europe. The company collaborates with contract research organizations and clinical centers worldwide to advance its studies, ensuring robust patient enrollment and regulatory engagement across major markets. Aurinia’s manufacturing partnerships support scalable production of its lead therapy, while its commercial infrastructure continues to evolve as Lupkynis reaches new patient populations. Under the leadership of an experienced management team with deep expertise in biopharmaceutical development and commercialization, Aurinia is committed to achieving sustainable growth through disciplined clinical execution and strategic alliances. The company’s board of directors includes industry veterans from both large pharmaceutical companies and innovative biotech startups. Aurinia remains focused on delivering transformative treatments to patients with high unmet medical needs and on building long‐term shareholder value through scientific innovation and operational excellence.AI Generated. May Contain Errors. Read More Aurinia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreAUPH MarketRank™: Aurinia Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 371st out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAurinia Pharmaceuticals has received no research coverage in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth409.09% Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is 30.82, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 26.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is 30.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.04.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 3.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Aurinia Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.39% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 4.84%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.39% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 6.9.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 4.84%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News Sentiment1.81 News SentimentAurinia Pharmaceuticals has a news sentiment score of 1.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest32 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 3% compared to the previous 30 days.MarketBeat Follows4 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Stock News HeadlinesThe Play On Aurinia Pharmaceuticals: Rising Cash Flow Provides OpportunityJuly 7, 2025 | seekingalpha.comAurinia Pharmaceuticals (AUPH) Gets a Buy from TD CowenJuly 3, 2025 | theglobeandmail.comThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the same point in every cycle when crypto enters its most explosive phase — and two experts are showing how to ride it. Inside The Crypto Code Workshop, you’ll get their step-by-step system and $10 in free Bitcoin for attending.July 18 at 2:00 AM | Crypto Swap Profits (Ad)Aurinia Pharmaceuticals Inc News (AUPH) - Investing.comJuly 3, 2025 | investing.comAUPH - Aurinia Pharmaceuticals Inc News - MorningstarJuly 2, 2025 | morningstar.comMAurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)June 30, 2025 | businesswire.comAurinia Pharmaceuticals Inc (AUPH) Announces Webcast for AUR200 Phase 1 Study Results | AUPH ...June 29, 2025 | gurufocus.comAurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025June 29, 2025 | financialpost.comFSee More Headlines AUPH Stock Analysis - Frequently Asked Questions How have AUPH shares performed this year? Aurinia Pharmaceuticals' stock was trading at $8.98 on January 1st, 2025. Since then, AUPH shares have decreased by 3.9% and is now trading at $8.63. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its quarterly earnings data on Monday, May, 12th. The biotechnology company reported $0.16 EPS for the quarter, topping the consensus estimate of $0.08 by $0.08. The biotechnology company earned $62.47 million during the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a trailing twelve-month return on equity of 14.27% and a net margin of 16.11%. Read the conference call transcript. Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' top institutional investors include Public Employees Retirement System of Ohio (0.02%), Acropolis Investment Management LLC (0.02%), City Center Advisors LLC (0.02%) and Wealth Enhancement Advisory Services LLC (0.01%). Insiders that own company stock include Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/12/2025Today7/18/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUPH CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Price Target for Aurinia Pharmaceuticals$11.50 High Price Target$13.00 Low Price Target$10.00 Potential Upside/Downside+31.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)$0.28 Trailing P/E Ratio31.20 Forward P/E Ratio79.70 P/E GrowthN/ANet Income$5.75 million Net Margins16.11% Pretax Margin16.91% Return on Equity14.27% Return on Assets9.93% Debt Debt-to-Equity Ratio0.16 Current Ratio5.93 Quick Ratio5.26 Sales & Book Value Annual Sales$235.13 million Price / Sales5.04 Cash Flow$0.31 per share Price / Cash Flow28.69 Book Value$2.68 per share Price / Book3.27Miscellaneous Outstanding Shares135,100,000Free Float118,621,000Market Cap$1.18 billion OptionableOptionable Beta1.16 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:AUPH) was last updated on 7/18/2025 by MarketBeat.com Staff From Our Partners[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | SponsoredWill I be blacklisted?Porter Stansberry says a financial force bigger than 9/11 or COVID is already ripping through America — and mo...Porter & Company | SponsoredWhen your faith is put to the test, what will you do?Former CIA advisor Jim Rickards believes President Trump has just unlocked what the Bible foretold — a $150 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.